Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer.
about
The expression of syndecan-1 is related to the risk of endometrial hyperplasia progressing to endometrial carcinomaCarcinogenesis: The more we seek to know the more we need to know - Challenges in the post Genomic EraSyndecans in tumor cell adhesion and signalingPrognostic and clinical significance of syndecan-1 in colorectal cancer: a meta-analysisEpithelial syndecan-1 expression is associated with stage and grade in colorectal cancer.Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors.Estrogen receptor β induces antiinflammatory and antitumorigenic networks in colon cancer cells.Functional identification of distinct sets of antitumor activities mediated by the FKBP gene family.Endogenous synthesis of n-3 polyunsaturated fatty acids in Fat-1 mice is associated with increased mammary gland and liver syndecan-1.Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies.Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancerA new prognostic staging system for rectal cancer.Syndecan-1 and E-cadherin expression in differentiated type of early gastric cancerHigh glucose-induced intestinal epithelial barrier damage is aggravated by syndecan-1 destruction and heparanase overexpression.Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans.Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas.Peroxisome proliferator-activated receptor gamma-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells.Relationship between cell adhesion molecules expression and the biological behavior of gastric carcinoma.Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma.Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget.Meta-analysis of histopathological features of primary colorectal cancers that predict lymph node metastases.Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma.In vivo and in vitro regulation of syndecan 1 in prostate cells by n-3 polyunsaturated fatty acids.Syndecan-1 regulates FGF8b responses in S115 mammary carcinoma cells.Increased in vitro cytotoxicity of TNF-alpha analog LK-805 is based on the interaction with cell surface heparan sulfate proteoglycan.Expression of syndecan-4 and correlation with metastatic potential in testicular germ cell tumours.Changes of cell adhesion and extracellular matrix (ECM) components in cervical intraepithelial neoplasia.Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas.Epithelial and stromal syndecan-1 and -2 are distinctly expressed in oral- and cutaneous squamous cell carcinomas.An immunohistochemical study of colon adenomas and carcinomas: E-cadherin, Syndecan-1, Ets-1.Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation.Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas.
P2860
Q24603990-4E3DDBC1-766B-4A50-9E29-7D1F567D65BBQ24801574-EE67B343-1A41-448E-841D-555D0F6077FEQ24807364-373793DB-B0D7-4EC3-8B4C-311C14F3C186Q26777707-72EDF8CB-45BF-4D2F-8CFB-175F9EC35385Q33219573-3A636CD3-0256-463B-9821-8AD9DFD2AB66Q33347864-813AD579-0B89-433D-BAED-66DFF397E774Q33636941-523BEE40-6F6E-4A2B-901B-759C1FE97532Q33716268-70BBC043-C6E7-4A83-95C3-16117BB005DEQ33927026-3F046B6B-835A-4956-8D4B-F90D2C96A4D8Q34039967-CE4B3647-3463-489F-96F6-F530928B0129Q34499650-1ECAACD2-9DFE-413F-9382-BB0FDD404DD2Q34551956-775281B6-F299-43B8-B569-8AEA56B6BD07Q35010363-A3FA1901-E983-4435-A033-1F0901D5BB8DQ35695593-3C3B7FBD-B44A-452A-AF44-0BE338C33B51Q35768137-6C1CE0EF-888D-45F2-A7B8-EC5127F052DFQ36740664-030F5C0C-C7B5-4B15-82BF-10513B14435AQ36940157-4930DD82-BE24-445F-8580-36B06FB765C5Q37240372-1476D865-BE45-4F8A-8C14-8E25673A663AQ37525296-62501F49-3721-4AAC-9CCC-215804A69EB0Q37840946-49735F00-239F-44F2-AECF-2AC34C1DCBA2Q37977032-ABFF12A8-3630-44FE-A8C5-88D6DE2B72D7Q38437960-D38A496A-F186-4863-992D-01727FB8D884Q39599906-001D5FD3-A10B-4B89-80AC-78145E5FDAC3Q40262635-363DE51C-D33E-4D5B-A3C6-9BDA6A9B01B0Q40683154-BEF51465-C13C-44FD-BC9C-3E3C49A32593Q41444734-98742B22-9F5A-430F-972D-C71FEB379CF4Q42476256-54B63B5A-691A-4D98-A4DC-32613DFF4381Q48136626-21930CC5-5EE7-4A05-BD30-A66980590BB8Q48923743-DA3DEBC0-1F4C-4B59-B9F3-DD61EFA7EDCAQ50883313-9CFC549E-D714-4B95-B25D-0DC50BB5A05CQ51791418-FBFD44E8-A978-4C18-8574-B77FC00FF9B8Q53377592-A43BA867-0C1A-4240-A78D-6F9D646CE8DFQ54722719-20274243-43C6-4F2E-92EF-0E828DB983FB
P2860
Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Reduced expression of syndecan ...... tients with colorectal cancer.
@en
Reduced expression of syndecan ...... tients with colorectal cancer.
@nl
type
label
Reduced expression of syndecan ...... tients with colorectal cancer.
@en
Reduced expression of syndecan ...... tients with colorectal cancer.
@nl
prefLabel
Reduced expression of syndecan ...... tients with colorectal cancer.
@en
Reduced expression of syndecan ...... tients with colorectal cancer.
@nl
P2093
P2860
P1476
Reduced expression of syndecan ...... tients with colorectal cancer.
@en
P2093
P2860
P304
P356
10.1111/J.1349-7006.2001.TB01062.X
P577
2001-10-01T00:00:00Z